Pfizer PFE.F (XETRA) €21.64 pre-market 29 Jan 2026: Feb 3 earnings will guide
The PFE.F stock opened pre-market at €21.64 on 29 Jan 2026, trading down -2.24% from yesterday as investors size up an upcoming earnings release on 03 Feb 2026. Pfizer Inc. (PFE.F) shows a trailing EPS of €1.48 and a PE of 14.62, metrics investors will weigh against COVID-19 revenue declines and pipeline news. Ahead of the report we focus on valuation, near-term catalysts, and Meyka AI’s model projection to frame trading scenarios for XETRA-listed Pfizer in Germany.
Earnings calendar and near-term catalysts
Pfizer reports results on 03 Feb 2026 and the earnings call is the primary short-term catalyst. The company has flagged continued pressure from lower COVID-19 product demand, while new trial results for oncology and obesity candidates could offset headwinds. Analysts will watch revenue growth, operating margin, and free cash flow per share. Any guidance change will likely drive volatility in the PFE.F stock on XETRA and influence supranational pricing discussions.
Recent performance and valuation snapshot
PFE.F stock trades at €21.64, with a 52-week range of €18.77–€25.95 and intraday spread €21.64–€22.06. Volume of 39,482 shares beats the 50-day average of 13,783 indicating higher interest. Key ratios: EPS €1.48, PE 14.62, price/ book 1.58, and dividend per share €1.76 (payout ratio 0.99). These metrics place Pfizer below the healthcare sector average PE of 33.55, highlighting a value tilt versus peers.
Meyka AI grade and model forecast
Meyka AI rates PFE.F with a score of 67.87 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Meyka AI’s forecast model projects a 1-year price of €19.76, implying an estimated downside of -8.68% versus the current €21.64. Forecasts are model-based projections and not guarantees. For our data and portfolio pages see Meyka stock profile: Meyka PFE.F page.
Technical setup and liquidity on XETRA
Momentum is neutral with RSI 52.93 and MACD near zero (histogram 0.03). Bollinger bands sit at €20.96–€22.43, so the stock trades near the middle band. Average volume and recent spikes show elevated trading interest in Germany. On balance volume (OBV) is positive at 199,945, while ATR is €0.40, indicating modest intraday volatility. Traders may watch a break above €22.43 for a short-term bullish signal or a fall below €20.96 for bearish confirmation.
Risks and upside drivers for investors
Primary risks include prolonged patent expiries, pricing pressure from Medicare negotiations, and weaker COVID-19 receipts. Regulatory or pricing moves could shave several percentage points from revenue. Upside comes from successful launches in oncology (BRAFTOVI data) and a potential consumer obesity franchise. Strategic deals and manufacturing contracts could also improve margins. Recent coverage highlights drug pricing debate and pipeline updates that may reshape consensus estimates (MarketWatch source and market commentary (Investing.com source).
Price targets and scenario planning
We outline three practical price targets for PFE.F stock using valuation and catalyst scenarios: conservative €18.00 (earnings miss, downside -16.83%), base €22.50 (in-line results and stable pipeline, upside +3.98%), bull €27.00 (positive surprise on launches, upside +24.79%). These targets reflect PE expansion/contraction and recurring free cash flow strength shown in Pfizer’s key metrics (free cash flow yield 7.06%). Investors should align position size to risk tolerance and dividend exposure.
Final Thoughts
Key takeaways for PFE.F stock: near-term movement will be driven by the 03 Feb 2026 earnings release and any guidance update. At €21.64, Pfizer trades at a modest PE 14.62 and yields a high dividend payout, but faces revenue pressure from COVID-19 product declines and potential pricing headwinds. Meyka AI’s model projects €19.76 for the year, implying -8.68% versus today’s price; this highlights a cautious baseline scenario. Our scenario price targets range from €18.00 (conservative) to €27.00 (bull). Use earnings as a decision point: monitor revenue mix, operating margin, and pipeline news. Forecasts are model-based projections and not guarantees. Meyka AI provides this analysis as an AI-powered market analysis platform to help frame risk and opportunity for XETRA-listed Pfizer.
FAQs
What drives short-term moves in PFE.F stock?
Short-term moves are led by earnings releases, guidance shifts, and pipeline trial data. Regulatory decisions and drug pricing discussions also cause volatility, as does demand swing in COVID-19 products.
How does Meyka AI view Pfizer’s valuation?
Meyka AI notes a modest valuation: PE 14.62, price/book 1.58, and free cash flow yield 7.06%. The firm assigns a 67.87/100 grade (B, HOLD) balancing value against growth risks.
What is a practical price target for PFE.F stock after earnings?
Post-earnings targets: conservative €18.00, base €22.50, bull €27.00. Use earnings outcomes and guidance to choose the scenario that fits your risk profile.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
